Remarkably, the TLR7-NP-adjuvanted influenza vaccine induced early and markedly improved titres of subdominant HA-stem specific antibodies and generated effective cross-protection against heterologous influenza viral challenge. The gene discussed is TLR7; the disease is influenza.